Purpose

The purpose of this study is to determine if treatment with a single dose of RE104 for Injection reduces anxiety symptoms in participants with Generalized Anxiety Disorder (GAD) as compared to placebo.

Condition

Eligibility

Eligible Ages
Between 18 Years and 74 Years
Eligible Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Has Generalized Anxiety Disorder as defined by DSM-5-TR - If female is not pregnant or planning to become pregnant. If male is not planning to make a partner pregnant. - Is willing and able to comply with the conditions and requirements of the study

Exclusion Criteria

  • Has a significant risk of suicide - Has an active or medical history of bipolar disorder, schizophrenia, schizoaffective disorder, psychotic disorder and/or borderline personality disorder, or first-degree family history of psychosis or bipolar disorder - Has other concurrent psychiatric disorders that is the primary disorder. - Has other medically significant conditions rendering unsuitability for the study - Has used or will need to use prohibited medications or therapies - Has a known sensitivity or intolerance to study intervention or potential rescue medications

Study Design

Phase
Phase 2
Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel Assignment
Primary Purpose
Treatment
Masking
Triple (Participant, Investigator, Outcomes Assessor)

Arm Groups

ArmDescriptionAssigned Intervention
Placebo Comparator
Placebo
A single subcutaneous injection of 0.9% sodium chloride for injection
  • Drug: Placebo
    Single, subcutaneous dose of 0.9% sodium chloride for injection
Experimental
30 mg RE104
A single subcutaneous injection of 30 mg RE104 for Injection
  • Drug: RE104 for Injection
    Single, subcutaneous dose of RE104 for Injection

Recruiting Locations

Lighthouse Psychiatry
Gilbert, Arizona 85234
Contact:
Matt Longson
435-268-5800
Contact@neosciclinicalresearch.com

Open Mind Therapeutics
San Francisco, California 94114
Contact:
Victoria Vega
415-906-7399
victoria@openmindcollective.org

TRIP Clinic at Psychedelic Science Institute
Santa Monica, California 90404
Contact:
Ashley Ramos
trialadmin@psychedlicsci.com

University of South Florida
Tampa, Florida 33613
Contact:
Genesis Estramera
813-974-1404
gestramera@usf.edu

Atlanta Center for Medical Research
Atlanta, Georgia 30331
Contact:
Amber Tannahill
404-881-5800
a.tannahill@cenexel.com

CenExel iResearch, LLC
Decatur, Georgia 30030
Contact:
Michael Mahaffrey
m.mahaffrey@cenexel.com

UNM Research Program Psychedelic Therapies
Albuquerque, New Mexico 14624
Contact:
Hector Garcia
505-675-0582
hecgarcia@salud.unm.edu

Summit Headlands LLC
Portland, Oregon 97210
Contact:
Tyler Leecing
tyler.leecing@summitnetwork.com

Austin Clinical Trial Partners
Austin, Texas 78737
Contact:
Kara Chilek
512-521-0595
studyinfo@austinCTP.com

Aim Trials, LLC
Plano, Texas 75093
Contact:
Sonia Prashar
214-856-2778
sonia.prashar@aimtrials.com

Cedar Clinical Research
Draper, Utah 84020
Contact:
Jane Bjorklund
801-369-4219
jane.bjorklund@numinusnetwork.com

Inner Space State Street
Orem, Utah 84058
Contact:
Janet Jimenez
801-871-5516
apply@innerspaceresearch.com

More Details

Status
Recruiting
Sponsor
Reunion Neuroscience Inc

Study Contact

Mark Pollack Chief Medical Officer, M.D.
1-888-880-REUN
info@reunionneuro.com

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.